Form D · Venture Capital Fund

Valence Advantage Life Sciences Fund II, L.P.

New York, NY · CIK 0001544406

Offering snapshot reported Mar 14, 2013 · SEC filing

Reported sold: $60.8M
Investors reported: 11
Minimum accepted: $0
First sale: Mar 30, 2012

What changed?

Latest filing versus its linked predecessor, where available.

Reported investors0 → 11

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 14, 2013	Amendment	$60,800,000	No comparison	11	SEC filing
Mar 14, 2012	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06, 3C, 3C.7
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $67.9K
Form D file number: 021-174950

Total amount includes a commitment of the General Partner.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Benedetto Gartland & Company, Inc.	24083	Benedetto Gartland & Company, Inc. · CRD 24083

Source: Form D, filed Mar 14, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

VALENCE ADVANTAGE LIFE SCIENCES FUND II, LP

Investment adviser: VALENCE LIFE SCIENCES, LLC

Gross asset value: $59.4M
Beneficial owners: 14
ADV minimum commitment: $0

Reported in Form ADV on Jun 7, 2013. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator INVESTMENT PARTNERSHIP SERVICES LLC BOSTON, Massachusetts, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor KPMG LLP NEW YORK, New York, United States

Custodian PERSHING LLC JERSEY CITY, New Jersey, United States Related to adviser: No

Marketer BENEDETTO, GARTLAND & COMPANY, INC. NEW YORK, New York, United States Related to adviser: No

Prime broker CREDIT SUISSE SECURITIES (USA) LLC NEW YORK, New York, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

PERSHING LLC
SEC 8-17574

BENEDETTO, GARTLAND & COMPANY, INC.
CRD 24083 · SEC 8-40919

CREDIT SUISSE SECURITIES (USA) LLC
CRD 816 · SEC 8-422

Filing source

Form ADV 741650 · Jun 7, 2013 · Schedule D 7.B.(1), fund 805-3436476673

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Jay Cecil	Director
A. Rachel Leheny	Director
Scott Morenstein	Director
Eric W. Roberts	Director
N/A Valence Life Sciences Gp Ii, Llc	Promoter

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

500 Park Avenue, 9 Th Floor
New York, NY, 10022